Bausch & Lomb BLCO
NYSE BLCO
$17.56 -0.23 (-1.29%)
As of: Sep 10, 2026 · 3:59 PM EDT

Bausch & Lomb (BLCO) Income from Continuing Operations (2021 - 2026)

Bausch & Lomb's (BLCO) quarterly Income from Continuing Operations came in at -$10.0 million in Q2 2026, up 82.76% on a YoY basis from -$5.5 million in Q2 2025, and up 85.71% quarter-over-quarter from -$70.0 million in Q1 2026.

Analysis

Bausch & Lomb (BLCO) Income from Continuing Operations (2021 - 2026) Analysis & Trends

Bausch & Lomb (BLCO) has reported Income from Continuing Operations for 6 consecutive years, with -$10.0 million the latest figure, recorded in Q2 2026.

  • For the quarter ending Q2 2026, Income from Continuing Operations rose 82.76% year-over-year to -$10.0 million; the trailing twelve-month figure through Jun 2026 stood at -$163.0 million (up 38.02% YoY), and the FY2025 full-year result was -$352.0 million, down 15.41% from the prior year.
  • Income from Continuing Operations grew to -$10.0 million in Q2 2026 per BLCO's latest filing, from -$70.0 million in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at $23.0 million in Q1 2022 and bottomed at -$211.0 million in Q1 2025.
  • Historically, Income from Continuing Operations has averaged -$57.1 million across 5 years, with a median of -$51.0 million in 2023.
  • The sharpest annual moves came in 2024 and 2025: Income from Continuing Operations jumped 110.0% in 2024, then sank 2800.0% in 2025.
  • Over 5 years, Income from Continuing Operations stood at -$15.0 million in 2022, then plunged by 240.0% to -$51.0 million in 2023, then jumped by 96.08% to -$2.0 million in 2024, then tumbled by 2800.0% to -$58.0 million in 2025, then jumped by 82.76% to -$10.0 million in 2026.
  • According to Business Quant data, Income from Continuing Operations over the past three periods registered -$10.0 million, -$70.0 million, and -$58.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Income (Continuing) (Qtr)
1 Abbott Laboratories 179.79 Bn 174.18 Bn 7.27 Bn 928.00 Mn
2 Intuitive Surgical 127.69 Bn 122.47 Bn 1.96 Bn 823.20 Mn
3 Medtronic 117.23 Bn 108.41 Bn 6.34 Bn 1.48 Bn
4 Stryker 103.55 Bn 100.07 Bn 4.50 Bn 1.28 Bn
5 Boston Scientific 63.24 Bn 62.70 Bn 3.85 Bn 905.00 Mn
6 Edwards Lifesciences 49.97 Bn 45.72 Bn 1.35 Bn 241.40 Mn
7 Alcon 32.83 Bn 31.37 Bn 1.68 Bn -92.00 Mn
8 Dexcom 32.30 Bn 30.35 Bn 830.00 Mn 249.10 Mn
9 Steris 20.73 Bn 20.25 Bn 684.20 Mn 201.00 Mn
10 Bausch & Lomb 6.28 Bn 5.90 Bn 867.00 Mn -10.00 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -10.00 Mn
Mar 31, 2026 -70.00 Mn
Dec 31, 2025 -58.00 Mn
Sep 30, 2025 -25.00 Mn
Jun 30, 2025 -58.00 Mn
Mar 31, 2025 -211.00 Mn
Dec 31, 2024 -2.00 Mn
Sep 30, 2024 8.00 Mn
Jun 30, 2024 -148.00 Mn
Mar 31, 2024 -163.00 Mn
Dec 31, 2023 -51.00 Mn
Sep 30, 2023 -80.00 Mn
Jun 30, 2023 -29.00 Mn
Mar 31, 2023 -88.00 Mn
Sep 30, 2022 -15.00 Mn
Jun 30, 2022 7.00 Mn
Mar 31, 2022 23.00 Mn
Dec 31, 2021 54.00 Mn
Sep 30, 2021 63.00 Mn
Jun 30, 2021 46.00 Mn